State Key Laboratory of Cancer Biology HB

Beijing, China

State Key Laboratory of Cancer Biology HB

Beijing, China
SEARCH FILTERS
Time filter
Source Type

Bian H.,State Key Laboratory of Cancer Biology HB | Zheng J.S.,State Key Laboratory of Cancer Biology HB | Nan G.,State Key Laboratory of Cancer Biology HB | Li R.,State Key Laboratory of Cancer Biology HB | And 15 more authors.
Journal of the National Cancer Institute | Year: 2014

To assess the efficacy of combining radioimmunoconjugate [(131)I] metuximab with radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) treatment compared with RFA alone, a single-center randomized controlled trial was conducted on 127 patients with Barcelona Clinic Liver Cancer staging system (BCLC) classifications of 0-B stage. Patients received either RFA followed by [(131)I] metuximab (n = 62) or RFA alone (n = 65). The primary outcome was overall tumor recurrence. Statistical tests were two-sided. The one- and two-year recurrence rates in the combination group were 31.8% and 58.5%, whereas those in the RFA group were 56.3% and 70.9%, respectively. The median time to overall tumor recurrence was 17 months in the combination group and 10 months in the RFA group (P = .03). The RFA-[(131)I] metuximab treatment showed a greater antirecurrence benefit than RFA in the metuximab target (ie, CD147)-positive subpopulation (P = .007). [(131)I] metuximab may yield prevention of tumor recurrence after RFA. © The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Loading State Key Laboratory of Cancer Biology HB collaborators
Loading State Key Laboratory of Cancer Biology HB collaborators